A Relative Bioavailability Study of Danoprevir and Ritonavir in Healthy Volunteers
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This single dose, randomized, open-label, 6 sequence, 3-period, crossover study will evaluate
the relative bioavailability of danoprevir and ritonavir in healthy volunteers. In Part 1,
subjects will be randomized to receive single oral doses of one of three tablet formulations
of danoprevir plus the reference ritonavir formulation, with an at least 7-day washout
between periods. In Part 2, subjects will be randomized to receive single oral doses of one
of three tablet formulations of ritonavir plus the reference formulation of danoprevir, with
at least a 7-day washout betwen periods. The anticipated time on study is up to 30 days.